MSH2 and neurofibromatosis type 1: In summary, non-pathogenic germline MSH2 variants and MSH2 promotor methylation was shown to be associated with the extent of neurofibroma manifestation in NF1 patients (without microdeletions) indicating an influence on MMR activity.